An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

Table 3 Health economic outcomes by infection type and pathogen (unadjusted)^a–c

	Abscess		Cellulitis		Wound
By infection type^d	Daptomycin	Vancomycin	Daptomycin	Vancomycin	Daptomycin	Vancomycin
By infection type^d	(n = 40)	(n = 42)	(n = 54)	(n = 44)	(n = 17)	(n = 16)
IRLOS, hours, mean (SD)	83.8 (53.8)	102.1 (75.4)	97.3 (61.5)	80.2 (43.5)	94.4 (63.4)	109.0 (59.0)
Total LOS, hours, mean (SD)	94.8 (102.2)	105.6 (75.2)	101.7 (64.4)	85.1 (56.6)	103.0 (58.9)	139.3 (94.3)
Total inpatient cost, 2012 US$, mean (SD)^a	9515 (8501)	9432 (5955)	9871 (5805)	7415 (4750)	9814 (5927)	13,101 (7025)
	Staphylococcus aureus ^e		MRSA		MSSA
By pathogen	Daptomycin	Vancomycin	Daptomycin	Vancomycin	Daptomycin	Vancomycin
By pathogen	(n = 58)	(n = 43)	(n = 39)	(n = 27)	(n = 14)	(n = 10)
IRLOS, hours, mean (SD)	98.4 (64.5)	101.2 (69.4)	98.5 (67.0)	85.9 (51.8)	84.5 (43.6)	136.2 (95.5)
Total LOS, hours, mean (SD)	109.0 (95.9)	105.4 (69.3)	111.3 (108.5)	92.3 (53.7)	93.0 (54.2)	136.2 (95.5)
Total inpatient cost, 2012 US$, mean (SD)^a	10,508 (8109)	9604 (5691)	10,692 (9171)	8854 (4119)	8967 (4084)	11,308 (8345)

IRLOS infection-related length of stay, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible Staphylococcus aureus, SD standard deviation, WAC wholesale acquisition cost
^aMultivariate analysis sample of 115 daptomycin and 106 vancomycin patients
^bWAC cost estimates using “waste” algorithm
^cThe P value was nonsignificant for all comparisons between daptomycin and vancomycin
^dFour daptomycin and four vancomycin patients had other infection types
^eIncludes known S. aureus infection for those patients with a culture; please note 5 daptomycin and 6 vancomycin patients were dropped from the MRSA/MSSA subgroup analyses mostly due to missing data

ISSN: 1471-2334